Could This Be the Next Big Trend in the Cannabis Industry?

OgraniGram Holdings Inc (TSX:OGI)(NASDAQ:OGI) is an example of a cannabis company that has looked to differentiate itself from its competition by investing in what could be a huge segment of the market.

| More on:
question marks written reminders tickets

Image source: Getty Images

The edibles market is just months away from going live in Canada. However, if it’s anything like last year’s marijuana launch, consumers and investors alike could be disappointed.

Supply is still an issue and the retail market is still not operating anywhere near where it could be. That’s why it may come as no surprise that many consumers are still purchasing pot from the black market — and why that’s not likely to stop anytime soon.

However, purchasing from the underground exposes consumers to risks, and one alternative is to make cannabis products at home. With prices for pot being expensive in retail pot shops and consumers having to pay taxes on it, there’s definitely an incentive for consumers to find alternatives.

While those options are normally often limited to growing flower, there are even ways consumers can make edibles and their own cannabis-infused gummies.

Company gets around cannabis restrictions with kit that requires key ingredient

B.C.-based Paracanna sells consumers a kit where they can simply add cannabis to produce a variety of infused gummy candies. While perhaps not offering as many flavours as what consumers could get in the retail market, the company still gives users many options.

The market for this type of product is sure to soar with the launch of edibles, especially if consumers get turned off at the high price points. There are many kits online when it comes to growing and making cannabis.

In addition, there are hundreds of cannabis cookbooks on Amazon that can help consumers make their own infused products. Whether it’s growing the flower itself or making edibles, there could be lots of demand from consumers seeking cheaper options for making cannabis products.

Why finding a niche is important for cannabis companies

The number of cannabis companies popping up in the industry is going to mean that trying to get market share is will prove challenging. That’s where finding a more specialized area to focus on could be advantageous.

OrganiGram Holdings Inc (TSX:OGI)(NASDAQ:OGI) is a great example of a company that has looked to a specific segment where it can dominate with fewer competitors than in a more generic space.

The company invested in a product line earlier this year that will help OrganiGram produce quality chocolate cannabis products. By tapping into the popularity of chocolate, OrganiGram could end up producing products that can appeal to both cannabis and chocolate lovers.

For the company, it’s a clever way to tap into what could be a very profitable segment of the market while not having to worry about competing head-on with a growing number of competitors.

It wouldn’t be surprising to witness other companies follow in the footsteps of Organigram, especially if they get squeezed out of larger segments and struggle financially.

With minimal barriers to entry in this industry, finding a way for a company to differentiate itself from its peers is going to be paramount in being able to not only grabbing market share, but also being able to post a profit as well.

OrganiGram’s venture into chocolate could prove to be a big winner, and focusing on do-it-yourself cannabis kits could be another area for companies to set their sights on.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

John Mackey, CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool’s board of directors. Fool contributor David Jagielski has no position in any of the stocks mentioned. David Gardner owns shares of Amazon. The Motley Fool owns shares of Amazon.

More on Cannabis Stocks

edit Jars of marijuana
Cannabis Stocks

Is Tilray Stock a Buy in the New Bullish Market?

Canadian cannabis producer Tilray has underperformed the broader markets in the last five years due to its weak fundamentals.

Read more »

Bad apple with good apples
Cannabis Stocks

1 TSX Stock I Wouldn’t Touch With a 10-Foot Pole

Down 99% from all-time highs, Aurora Cannabis stock remains a high-risk bet due to its weak fundamentals and risky liquidity…

Read more »

A cannabis plant grows.
Cannabis Stocks

Canopy Growth Stock Has Been on a Roller Coaster: Is it a Good Buy?

In their relatively small lifetime, most cannabis stocks in Canada have seen both extreme highs and massive slumps. But their…

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Canopy Growth Stock Surged 100% Last Month: Is It a Good Buy Now?

Canopy Growth soared more than 160% last month. Can the TSX cannabis stock continue to mover higher in 2024?

Read more »

A cannabis plant grows.
Cannabis Stocks

Canopy Growth Stock Is Rising But I’m Worried About This One Thing

Canopy Growth stock is soaring as the legalization effort makes real progress in both Germany and the United States.

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Why Canopy Growth Stock Could Double in 2024

Canopy Growth (TSX:WEED) stock saw its share more than double in the last two weeks. So, can it do it…

Read more »

Coworkers standing near a wall
Cannabis Stocks

Why Is Everyone Talking About Canopy Growth Stock?

Canopy Growth stock (TSX:WEED) saw shares surge in the last two weeks for a variety of reasons investors can dig…

Read more »

Pot stocks are a riskier investment
Stocks for Beginners

Why Shares of Cannabis Stocks Are Rising This Week

Cannabis stocks received a boost this week as the White House urged the drug enforcement administration to reschedule the drug.

Read more »